Country: Ísrael
Tungumál: enska
Heimild: Ministry of Health
MECASERMIN
MEDISON PHARMA LTD
H01AC03
SOLUTION FOR INJECTION
MECASERMIN 10 MG / 1 ML
S.C
Required
IPSEN PHARMA, FRANCE
MECASERMIN
For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (Primary IGFD).Severe Primary IGFD is defined by:* height standard deviation score ≤–3.0and* basal IGF-1 levels below the 2.5th percentile for age and genderand* GH sufficiency.* Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment.In some cases, when deemed necessary, the physician may decide to assist in the diagnosis by performing an IGF-I generation test.
2020-01-27
INFORMATION FOR PARENTS, CAREGIVERS AND PATIENTS ABOUT HYPOGLYCEMIA AND WHAT TO DO IF IT DEVELOPS. This leaflet contains important information. Please read the entire leaflet carefully before starting to use the product. This medication is subject to additional monitoring in order to allow the rapid identification of new safety information. You can help by reporting any side effects that your child may experience. See the information regarding how to report side effects at the end of this leaflet. Before using the product, read the package leaflet, which includes detailed injection instructions. MECASERMIN The word "hypoglycemia" is the medical term for a low blood sugar level. If your child has been prescribed with Increlex, you must be familiar with the phenomenon of hypoglycemia and how to deal with it if it occurs. Increlex is similar to insulin, a naturally occurring hormone in the body that controls blood sugar levels, and therefore, Increlex can affect blood sugar levels and has a growth-promoting effects. As a result, hypoglycemia is a possible side effect of treatment with Increlex. If hypoglycemia develops, it usually occurs in the first month of treatment, and the problem lessens as the treatment continues. It is important that you read the following information because the chances of hypoglycemia developing, and any problems that it may cause can easily be minimized by taking some very simple precautions. What is hypoglycemia and why do I need to know about it? Two of the most important risk factors for hypoglycemia are: 1. INSUFFICIENT FOOD CONSUMPTION; FOR EXAMPLE, POSTPONING OR MISSING MEALS 2. PHYSICAL ACTIVITY WITHOUT EATING ENOUGH The following advice should be followed closely throughout the treatment with Increlex: Increlex injections should be administered shortly before or immediately after a meal (within 20 minutes) If a dose of Increlex cannot be administered shortly before or just after a meal, that dose should not be administered. The regular dose must be administered at the next schedul Lestu allt skjalið
INCR-SPC-1222-V1 Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Increlex . 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 10 mg of mecasermin*. Each vial of 4 ml contains 40 mg of mecasermin*. * Mecasermin is a recombinant DNA-derived human insulin-like growth factor-1(IGF-1) produced in Escherichia coli. Excipient with known effect: One ml contains 9 mg of benzyl alcohol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection Colourless to slightly yellow and clear to slightly opalescent liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (Primary IGFD). Severe Primary IGFD is defined by: • height standard deviation score –3.0 and • basal IGF-1 levels below the 2.5 th percentile for age and gender and • GH sufficiency. • Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. In some cases, when deemed necessary, the physician may decide to assist in the diagnosis by performing an IGF-I generation test. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION PATIENT SAFETY INFORMATION CARD The marketing of Increlex is subject to a risk management plan (RMP) including a ‘Patient safety information Card’, emphasizes important safety information that the patient should be aware of before and during treatment. Please explain to the patient the need to review the card before starting treatment. INCR-SPC-1222-V1 Page 2 of 13 Treatment with mecasermin should be directed by physicians who are experienced in the d Lestu allt skjalið